Eli Lilly Sees $2M Bearish Put Contract as Stock Trades Near 52-Week Lows
By TrendSpider Editor
A single unusual put contract on Eli Lilly and Company (LLY) worth $2,060,743 in premium has surfaced, flagging notable bearish positioning against the pharmaceutical giant. The contract targets a $1,240 strike, sitting meaningfully out of the money relative to LLY's current price of $1,364.35, whic
Eli Lilly Sees $2M Bearish Put Contract as Stock Trades Near 52-Week Lows
A single unusual put contract on Eli Lilly and Company (LLY) worth $2,060,743 in premium has surfaced, flagging notable bearish positioning against the pharmaceutical giant. The contract targets a $1,240 strike, sitting meaningfully out of the money relative to LLY's current price of $1,364.35, which itself sits closer to the bottom of its 52-week range of $850.51 to $1,453. With the stock down just 0.22% on the session, the options flow is the standout story today, suggesting at least one large player is bracing for further downside heading into the new year.
Key Drivers of the LLY Stock Move
- Main Catalyst: One unusual put contract was flagged on LLY with a $1,240 strike expiring January 15, 2027, carrying $2,060,743 in total premium. The contract saw 646 contracts trade against an open interest level that places today's volume at 302% of existing open interest, a signal of fresh, aggressive positioning rather than a hedge on an existing stake.
- Bull Case: The $1,240 strike sits well below the current price of $1,364.35, meaning LLY shares would need to fall roughly 9% from current levels before this put moves into the money. The stock has already pulled back sharply from its 52-week high of $1,453, and bulls could argue the worst of the selling has already been absorbed.
- Bear Case: The sheer premium committed, over $2 million on a single out-of-the-money put contract, points to a high-conviction directional bet on further downside. The January 15, 2027 expiration gives the trader more than two months for LLY to break below $1,240, and the 302% open interest ratio confirms this is not routine hedging activity.
Looking ahead, the forward setup for LLY is complicated by its position in the weight-loss drug race, where competitive pressures from rivals continue to generate headlines and investor uncertainty. The stock is currently trading closer to the lower half of its 52-week range, and any macro or clinical catalysts between now and mid-January could be the deciding factor for whether this put pays off. Investors should watch for pipeline updates, pricing news related to GLP-1 therapies, and any broader healthcare policy developments that could act as near-term triggers in either direction.
LLY Unusual Options Activity
One unusual contract was flagged in today's session for Eli Lilly:
- Type: Put | Strike: $1,240 | Expiry: January 15, 2027 | Volume: 646 contracts | Open Interest: 302% of existing OI (out of the money)
The 302% open interest ratio is a key detail here. When a contract's volume exceeds its open interest by this margin, it typically indicates new money entering a position rather than a rollover or existing hedge. With zero call contracts flagged in today's unusual flow, the options market activity is entirely skewed to the downside for LLY on this session.
LLY Seasonality
Historically, large-cap pharmaceutical stocks like LLY tend to see elevated options activity in the November to January window as institutional players position ahead of year-end portfolio rebalancing and early-year earnings catalysts. A January 15, 2027 expiration places this contract squarely within that seasonally active window, adding context to the timing of this unusually large put bet.
LLY Relative Performance
LLY's current price of $1,364.35 represents a meaningful retreat from its 52-week high of $1,453, with today's marginal decline of 0.22% keeping the stock in a broader consolidation pattern. At roughly 94% of its 52-week peak, Lilly has held up better than some large-cap biotech peers that have seen steeper drawdowns this year, though the gap between current price and the 52-week low of $850.51 underscores just how wide the trading range has been over the past year.
More on LLY
- Eli Lilly Hovers Just Below All-Time High as Stock Trades Near $1,444
- Eli Lilly Surges Toward 52-Week High as LLY Stock Approaches $1,460 Resistance
- Eli Lilly Holds Near All-Time Highs as Stock Dips Slightly to $1,429
- Eli Lilly Hovers Just Below All-Time High as Stock Climbs Toward $1,453 Resistance
- Jefferies Boosts Eli Lilly Price Target to $1,700 as Stock Nears 52-Week High
Latest Market News
- Palo Alto Networks Drops 7.94% Despite 20 Analyst Confirmations and $432 Average Price Target
- Meta Platforms Drops Nearly 6% as Shares Slide Toward 52-Week Low Territory
- Oracle Stock Craters 6.4%, Breaking Below Its 52-Week Low to $103.44
- QUALCOMM Shares Plunge 7.41% to $150.01, Nearing 52-Week Lows
- CrowdStrike Shares Crater 15% on Friday, Erasing Months of Gains in a Single Session
- Snowflake Shares Tumble 5.13% as Stock Retreats Sharply from Recent Highs